Blog

Dr Elin Haf Davies is the CEO & Founder of Aparito.

Dr Elin Haf Davies founded Aparito in 2014 on the back of 21 years of clinical (as Senior Clinical Research Nurse and Trial Administrator, Great Ormond Street Children’s Hospital, London), research (PhD, University College London, UK) and regulatory experience (as Scientific Assessor at both the Medicines Health Regulatory Authority (MHRA) and the European Medicine Agency (EMA)).

At the EMA Elin Haf was part of the core team responsible for implementing the E.U. Paediatric Regulation which came into force in January 2007.

Elin continues to be involved in the research and development of new and emerging drug treatments for rare diseases in children. Her PhD – focusing on developing new outcome measures for gait and ataxia in children with neuro-Lysosomal Storage Disorders resulted in many peer-reviewed journals. Since 2013, Elin Haf has been an Associate Fellow at the Centre for the Advancement of Sustainable Medical Innovation (CASMI) and an Academic Fellow at Bangor University since 2014 dedicated to the cost evaluation of orphan drugs.

Her considerable career in clinical, academic and regulatory fields, combined with extensive dialogue and collaboration with patient groups, means that she brings innovation and designs as a solution to all stakeholder groups. Elin’s passion has always been to inspire children, especially those with chronic illnesses, to be empowered and engaged in their own lives.

Aparito was founded as a tech solution to contribute to patient empowerment in the drug development pathway and completely transform the way clinical studies are conducted and novel eCOA are developed.

In addition to her work at Aparito, Elin is the Chair of Metabolic Support UK, the leading patient organisation for Inherited Metabolic Disorders supporting thousands of patients worldwide.

 Dr Rashmi Narayana is the Chief Scientific Officer at Aparito

Rashmi qualified as a psychiatrist and made her way to healthtech via leadership roles at the American Red Cross, academia, and research management. She has held roles as Clinical Director at uMotif,  as Head of Clinical Development and Head of Clinical and Regulatory Affairs at Huma and, as Director of Operations at Our Mobile Health.

She has numerous peer-reviewed publications to her name. She holds a Masters in Public Health from the London School of Hygiene and Tropical Medicine and an MBA from Imperial College Business School, London.  Over the pandemic, she trained and certified as a leadership coach.  

Dr Elisa Ferrer Mallol is the Patient Advocacy Manager at Aparito.

Elisa holds a Pharmacy degree and a PhD in physiology. She has broad experience in different areas of the healthcare industry, such as drug safety, medical publishing and research project management.

In the last few years, she worked in the rare disease patient advocacy space, first at EURORDIS, the European umbrella of rare disease patient organisations, and now at Aparito, managing the Patient Group Accelerator, a programme to help co-design digital endpoints in partnership with patient groups.